Daiichi Sankyo Company, Limited の製品パイプライン分析2016

◆英語タイトル:Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016
◆商品コード:DATA70209175
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年10月12日
◆ページ数:196
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥168,000見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Daiichi Sankyo Company, Limited – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘Daiichi Sankyo Company, Limited – Product Pipeline Review – 2016’, provides an overview of the Daiichi Sankyo Company, Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Daiichi Sankyo Company, Limited
- The report provides overview of Daiichi Sankyo Company, Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Daiichi Sankyo Company, Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Daiichi Sankyo Company, Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Daiichi Sankyo Company, Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Daiichi Sankyo Company, Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Daiichi Sankyo Company, Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Daiichi Sankyo Company, Limited Snapshot 6
Daiichi Sankyo Company, Limited Overview 6
Key Facts 6
Daiichi Sankyo Company, Limited – Research and Development Overview 7
Key Therapeutic Areas 7
Daiichi Sankyo Company, Limited – Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products – Monotherapy 16
Pipeline Products – Combination Treatment Modalities 17
Pipeline Products – Partnered Products 18
Pipeline Products – Out-Licensed Products 20
Daiichi Sankyo Company, Limited – Pipeline Products Glance 22
Daiichi Sankyo Company, Limited – Late Stage Pipeline Products 22
Daiichi Sankyo Company, Limited – Clinical Stage Pipeline Products 24
Daiichi Sankyo Company, Limited – Early Stage Pipeline Products 27
Daiichi Sankyo Company, Limited – Unknown Stage Pipeline Products 30
Daiichi Sankyo Company, Limited – Drug Profiles 31
A-503451A – Drug Profile 31
CS-1050 – Drug Profile 32
DC-159a – Drug Profile 33
denosumab – Drug Profile 34
DF-461 – Drug Profile 43
Drug to Inhibit IDH1 for Acute Myelocytic Leukemia and Glioma – Drug Profile 44
Drugs for Oncology, Cardiovascular and Metabolic Diseases – Drug Profile 45
DS-1040 – Drug Profile 46
DS-1093 – Drug Profile 47
DS-1123 – Drug Profile 48
DS-1501 – Drug Profile 49
DS-1558 – Drug Profile 50
DS-1971 – Drug Profile 51
DS-2330 – Drug Profile 52
DS-2969 – Drug Profile 53
DS-3032 – Drug Profile 54
DS-3201 – Drug Profile 55
DS-5141 – Drug Profile 56
DS-5272 – Drug Profile 57
DS-5573a – Drug Profile 58
DS-6051 – Drug Profile 59
DS-7080 – Drug Profile 60
DS-8108b – Drug Profile 61
DS-8201 – Drug Profile 62
DS-8273 – Drug Profile 63
DS-8500 – Drug Profile 64
DS-8895 – Drug Profile 66
DS-9001 – Drug Profile 67
DS-9231 – Drug Profile 68
edoxaban tosylate – Drug Profile 69
efatutazone – Drug Profile 74
esaxerenone – Drug Profile 76
etanercept biosimilar – Drug Profile 78
etirinotecan pegol – Drug Profile 81
hydromorphone hydrochloride – Drug Profile 87
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine – Drug Profile 88
laninamivir – Drug Profile 89
mirogabalin besylate – Drug Profile 93
Monoclonal Antibodies for Undisclosed Indication – Drug Profile 95
Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer – Drug Profile 96
nimotuzumab – Drug Profile 97
patritumab – Drug Profile 101
Pedopeptins to Inhibit LPS for Bacterial Infection – Drug Profile 103
PLX-51107 – Drug Profile 104
PLX-73086 – Drug Profile 105
PLX-7486 – Drug Profile 106
PLX-8394 – Drug Profile 107
PLX-9486 – Drug Profile 108
prasugrel hydrochloride – Drug Profile 109
Protein for Undisclosed Indication – Drug Profile 113
quizartinib dihydrochloride – Drug Profile 114
R-xxx – Drug Profile 121
Small Molecule for Cardiovascular-Metabolic Diseases – Drug Profile 122
Small Molecule for Respiratory Tract Infections – Drug Profile 123
Small Molecule for Tuberculosis – Drug Profile 124
Small Molecule to Agonize Liver X Receptor for Atherosclerosis – Drug Profile 125
Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders – Drug Profile 126
Small Molecule to Antagonize VLA-4 for Asthma – Drug Profile 127
Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections – Drug Profile 128
Small Molecule to Inhibit HSL for Dyslipidemia – Drug Profile 129
Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis – Drug Profile 130
Small Molecule to Inhibit PDE4 for COPD – Drug Profile 131
Small Molecule to Inhibit PDE4B for Lung Inflammation – Drug Profile 132
Small Molecule to Inhibit Renin for Hypertension – Drug Profile 133
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis – Drug Profile 134
Small Molecules for Malaria – Drug Profile 135
Small Molecules for Multiple Neurodegenerative Diseases – Drug Profile 136
Small Molecules for Osteopenia and Osteoporosis – Drug Profile 137
Small Molecules to Agonize BRS-3 for Obesity – Drug Profile 138
Small Molecules to Agonize Pan PPAR for Multiple Sclerosis – Drug Profile 139
Small Molecules to Inhibit FATP1 for Undisclosed Indication – Drug Profile 140
Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases – Drug Profile 141
Small Molecules to Inhibit Nav1.7 for Pain – Drug Profile 142
Small Molecules to Inhibit p53-MDM2 Interaction for Cancer – Drug Profile 143
Sphaerimicin A – Drug Profile 144
SQ-641 – Drug Profile 145
Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease – Drug Profile 147
tivantinib – Drug Profile 148
U-31402 – Drug Profile 154
U-3771 – Drug Profile 155
U-3808 – Drug Profile 156
U3-1784 – Drug Profile 157
VN-0102 – Drug Profile 158
VN-0103 – Drug Profile 159
VN-0104 – Drug Profile 160
VN-0105 – Drug Profile 161
VN-100 – Drug Profile 162
Daiichi Sankyo Company, Limited – Pipeline Analysis 163
Daiichi Sankyo Company, Limited – Pipeline Products by Target 163
Daiichi Sankyo Company, Limited – Pipeline Products by Route of Administration 167
Daiichi Sankyo Company, Limited – Pipeline Products by Molecule Type 168
Daiichi Sankyo Company, Limited – Pipeline Products by Mechanism of Action 169
Daiichi Sankyo Company, Limited – Dormant Projects 173
Daiichi Sankyo Company, Limited – Discontinued Pipeline Products 176
Discontinued Pipeline Product Profiles 178
Daiichi Sankyo Company, Limited – Company Statement 183
Daiichi Sankyo Company, Limited – Locations And Subsidiaries 184
Head Office 184
Other Locations & Subsidiaries 185
Appendix 188
Methodology 188
Coverage 188
Secondary Research 188
Primary Research 188
Expert Panel Validation 188
Contact Us 188
Disclaimer 189

List of Tables
Daiichi Sankyo Company, Limited, Key Facts 13
Daiichi Sankyo Company, Limited - Pipeline by Indication, 2016 16
Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016 22
Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016 23
Daiichi Sankyo Company, Limited - Combination Treatment Modalities in Pipeline, 2016 24
Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016 25
Daiichi Sankyo Company, Limited - Partnered Products/ Combination Treatment Modalities, 2016 26
Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016 27
Daiichi Sankyo Company, Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 28
Daiichi Sankyo Company, Limited - Pre-Registration, 2016 29
Daiichi Sankyo Company, Limited - Phase III, 2016 30
Daiichi Sankyo Company, Limited - Phase II, 2016 31
Daiichi Sankyo Company, Limited - Phase I, 2016 32
Daiichi Sankyo Company, Limited - Preclinical, 2016 34
Daiichi Sankyo Company, Limited - Discovery, 2016 36
Daiichi Sankyo Company, Limited - Unknown, 2016 37
Daiichi Sankyo Company, Limited - Pipeline by Target, 2016 171
Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016 174
Daiichi Sankyo Company, Limited - Pipeline by Molecule Type, 2016 175
Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action, 2016 177
Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016 180
Daiichi Sankyo Company, Limited - Discontinued Pipeline Products, 2016 183
Daiichi Sankyo Company, Limited, Subsidiaries 192

List of Figures
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Indication, 2016 15
Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016 22
Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016 23
Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016 25
Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016 27
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Target, 2016 170
Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016 174
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Molecule Type, 2016 175
Daiichi Sankyo Company, Limited - Pipeline Products by Top 10 Mechanism of Action, 2016 176

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Daiichi Sankyo Company, Limited の製品パイプライン分析2016(Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆